211 related articles for article (PubMed ID: 10212525)
1. Essential drugs in the new international economic environment.
Velásquez G; Boulet P
Bull World Health Organ; 1999; 77(3):288-92. PubMed ID: 10212525
[TBL] [Abstract][Full Text] [Related]
2. Has the implementation of the TRIPS Agreement in Latin America and the Caribbean produced intellectual property legislation that favours public health?
Oliveira MA; Bermudez JA; Chaves GC; Velásquez G
Bull World Health Organ; 2004 Nov; 82(11):815-21. PubMed ID: 15640916
[TBL] [Abstract][Full Text] [Related]
3. TRIPS, pharmaceutical patents, and access to essential medicines: a long way from Seattle to Doha.
't Hoen E
Chic J Int Law; 2002; 3(1):27-46. PubMed ID: 15709298
[No Abstract] [Full Text] [Related]
4. A fair deal for the future: flexibilities under TRIPS.
So AD
Bull World Health Organ; 2004 Nov; 82(11):813. PubMed ID: 15640914
[No Abstract] [Full Text] [Related]
5. [Essential medicines and the TRIPS Agreement: collision between the right to health and intellectual property rights].
Allard Soto R
Salud Colect; 2015 Mar; 11(1):9-21. PubMed ID: 25853827
[TBL] [Abstract][Full Text] [Related]
6. Access to essential drugs, human rights and global justice.
Shalev C
Monash Bioeth Rev; 2004 Jan; 23(1):S56-74. PubMed ID: 15835024
[No Abstract] [Full Text] [Related]
7. The GO License: only part of the solution.
Batson A; Milstien JB
Health Aff (Millwood); 2008; 27(1):140-2. PubMed ID: 18180489
[TBL] [Abstract][Full Text] [Related]
8. Access to essential medicines: a Hobbesian social contract approach.
Ashcroft RE
Dev World Bioeth; 2005 May; 5(2):121-41. PubMed ID: 15842722
[TBL] [Abstract][Full Text] [Related]
9. The responsibility of research universities to promote access to essential medicines.
't Hoen EF
Yale J Health Policy Law Ethics; 2003; 3(2):293-300. PubMed ID: 14577145
[No Abstract] [Full Text] [Related]
10. Deadlock on access to cheap drugs at global trade negotiations.
Hagmann M
Bull World Health Organ; 2003; 81(2):150-1. PubMed ID: 12751424
[No Abstract] [Full Text] [Related]
11. Patent necessity: intellectual property dilemmas in the biotech domain and treatment equity for developing countries.
Spectar JM
Houst J Int Law; 2002; 24(2):227-78. PubMed ID: 16189914
[No Abstract] [Full Text] [Related]
12. TRIPS, pharmaceuticals, developing countries, and the Doha "solution".
Sykes AO
Chic J Int Law; 2002; 3(1):47-68. PubMed ID: 15709299
[No Abstract] [Full Text] [Related]
13. Ensuring access to essential medicines: some economic considerations.
Maskus KE
Spec Law Dig Health Care Law; 2003 Jul; (291):9-25. PubMed ID: 15206162
[No Abstract] [Full Text] [Related]
14. World pharmaceutical developments.
Bale H
World Hosp Health Serv; 2002; 38(2):1. PubMed ID: 12402745
[No Abstract] [Full Text] [Related]
15. Trade agreements, intellectual property, and the role of the World Bank in improving access to medicines in developing countries.
Rovira J
Yale J Health Policy Law Ethics; 2004; 4(2):401-13. PubMed ID: 15536921
[No Abstract] [Full Text] [Related]
16. Impact of India's new patents law 2005: a physician's perspective.
Lele RD
J Assoc Physicians India; 2005 Aug; 53():671-5. PubMed ID: 16398073
[No Abstract] [Full Text] [Related]
17. Intellectual property and access to ART: unwise choice of terminology.
Stallman R
PLoS Med; 2006 Nov; 3(11):e509; author reply e510. PubMed ID: 17132062
[No Abstract] [Full Text] [Related]
18. In wake of 9/11, drug-patent rules change.
Cassels A
CMAJ; 2002 Feb; 166(3):366. PubMed ID: 11868652
[No Abstract] [Full Text] [Related]
19. Essential AIDS medications in India.
Thomas J
Issues Med Ethics; 2000; 8(2):62. PubMed ID: 16323350
[No Abstract] [Full Text] [Related]
20. Basic survival needs and access to medicines--coming to grips with TRIPS: conversion + calculation.
Van Puymbroeck RV
J Law Med Ethics; 2010; 38(3):520-49. PubMed ID: 20880239
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]